SCHEMBL23345800

SCHEMBL23345800

O=P(O)(O)CCC1OC(n2cnc3c(NCc4ccccc4Cl)nc(Cl)nc32)C(O)C1O

nearest known ligand 0.79

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NT5E P21589 14/20 0.79
ADORA3 P0DMS8 4/20 0.59
ADORA2A P29274 2/20 0.56
PPARD Q03181 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23345799 1.00 NT5E (0.79) NT5EADORA3ADORA2APPARD
SCHEMBL26283317 1.00 NT5E (0.79) NT5EADORA3ADORA2APPARD
SCHEMBL23345784 0.94 NT5E (0.74) NT5EADORA3ADORA2A
SCHEMBL27043402 0.94 NT5E (0.74) NT5EADORA3ADORA2A
SCHEMBL23345783 0.94 NT5E (0.74) NT5EADORA3ADORA2A
SCHEMBL26282835 0.91 NT5E (0.66) NT5EADORA3ADORA2A
SCHEMBL23345953 0.91 NT5E (0.66) NT5EADORA3ADORA2A
SCHEMBL23345958 0.91 NT5E (0.66) NT5EADORA3ADORA2A
SCHEMBL23345532 0.90 NT5E (0.78) NT5EADORA3ADORA2A
SCHEMBL23345534 0.90 NT5E (0.78) NT5EADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 US disclosed
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2022-12-20 US disclosed
US-20210139526-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 NT5E 2/4885ADORA3 34/4885ADORA2A 17/4885
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof ENTPD5, ENTPD1, NT5E NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885
US-20210139526-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, ENTPD1, NT5E NT5E 3/4885ADORA3 35/4885ADORA2A 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.